摘要
目的探讨前列通胶囊联合盐酸坦索罗辛胶囊治疗前列腺炎的临床效果及对巨噬细胞炎性蛋白-1α(MIP-1α)、单核细胞趋化蛋白-1(MCP-1)水平的影响。方法选取2020年3月至2022年12月的90例前列腺炎患者为研究对象,按照随机数字表法将其分为对照组(45例,盐酸坦索罗辛胶囊)和观察组(45例,前列通胶囊联合盐酸坦索罗辛胶囊)。比较两组的治疗效果。结果观察组的治疗总有效率明显高于对照组(P<0.05)。治疗后,观察组的美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)各维度评分低于对照组(P<0.05)。治疗后,观察组的白细胞介素-1β(IL-1β)、MIP-1α、MCP-1水平低于对照组(P<0.05)。治疗后,观察组的最大尿流率高于对照组,膀胱颈长度短于对照组,最大尿道压力低于对照组(P<0.05)。结论前列通胶囊联合盐酸坦索罗辛胶囊治疗前列腺炎的效果满意,可有效改善症状,提高患者生活质量,抑制炎性因子表达,改善尿动力学指标,值得推广。
Objective To investigate the clinical effect of Qianlietong capsules combined with tamsulosin hydrochloride capsules in the treatment of prostatitis and its influences on macrophage inflammatory protein-1α(MIP-1α)and monocyte chemotactic protein-1(MCP-1)levels.Methods A total of 90 patients with prostatitis from March 2020 to December 2022 were selected as the research objects and divided into control group(45 cases,tamsulosin hydrochloride capsules)and observation group(45 cases,Qianlietong capsules combined with tamsulosin hydrochloride capsules)according to the random number table method.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI)scores of each dimension in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of interleukin-1β(IL-1β),MIP-1αand MCP-1 in the observation group were lower than those in the control group(P<0.05).After treatment,the maximum urinary flow rate of the observation group was higher than that of the control group,the bladder neck length was shorter than that of the control group,and the maximum urethral pressure was lower than that of the control group(P<0.05).Conclusion Qianlietong capsule combined with tamsulosin hydrochloride capsule in the treatment of prostatitis has satisfactory effect,it can effectively improve the symptoms,improve the quality of life of patients,inhibit the expression of inflammatory factors,and improve the urodynamic indexes,which is worth promoting.
作者
何万锁
戴晓刚
HE Wansuo;DAI Xiaogang(Xianyang Hospital of Yan'an University,Xianyang 712000;Xi'an International Medical Center Hospital,Xi'an 710100,China)
出处
《临床医学研究与实践》
2023年第36期33-36,共4页
Clinical Research and Practice
关键词
前列通胶囊
盐酸坦索罗辛胶囊
前列腺炎
临床症状
尿动力学
Qianlietong capsule
tamsulosin hydrochloride capsules
prostatitis
clinical symptom
urodynamic